DrugDashboards

Rifampin

rifampin · RIFAMPIN 300 mg/1 · Capsule · Oral · Epic Pharma, Llc

NDC 42806-0799-30 · 30 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $0.6802 per unit over the past year. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.6802per EAinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.9842per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$0.6921per CAPweighted avg manufacturer price $0.2573 · May 1, 2026102% of what pharmacies pay — higher than 57% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 68180-0659-07) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$1.12per unit
middle half $0.8761–$1.37 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $1.12
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$2.00$4.00$6.00Apr 2022Sep 2026$0.6802
54 price points · per EA · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$20.41
#90 count
$61.22

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2023)

$1,014
24 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

25● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • in shortage now+25

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for rifampin (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA064150
TE code
AB
Approval date
May 28, 1997
Patents / exclusivity
None on file

Shortage history

  • In shortage now — Rifampin, Capsule, 150 mg (NDC 42806-801-01)Dec 22, 2021
    Discontinuation of the manufacture of the drug
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 150 mg (NDC 42806-801-30)Dec 22, 2021
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 150 mg (NDC 68180-658-06)Dec 22, 2021
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 42806-799-01)Dec 22, 2021
    Discontinuation of the manufacture of the drug
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 42806-799-05)Dec 22, 2021
    Discontinuation of the manufacture of the drug
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 42806-799-30)Dec 22, 2021
    Discontinuation of the manufacture of the drug
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 42806-799-60)Dec 22, 2021
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 68180-659-06)Dec 22, 2021
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months
  • In shortage now — Rifampin, Capsule, 300 mg (NDC 68180-659-07)Dec 22, 2021
    month 57 — 4× the typical 14-month oral solid shortage · model puts 24% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of rifampin (Capsule)

LabelerStrengthFirst seenLast seen
A-S Medication SolutionsRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingRIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
American Health PackagingRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.RIFAMPIN 150 mg/1Jul 22, 2026Sep 2, 2026
ANI Pharmaceuticals, Inc.RIFAMPIN 300 mg/1Jul 22, 2026Sep 2, 2026
Bryant Ranch PrepackRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCRIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
Chartwell RX, LLCRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
Coupler LLCRIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
Epic Pharma, LlcRIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
Epic Pharma, LlcRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.RIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
Lupin Pharmaceuticals, Inc.RIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
Major PharmaceuticalsRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026
Puracap Laboratories Llc Dba Blu PharmaceuticalsRIFAMPIN 150 mg/1Jul 15, 2026Sep 2, 2026
Puracap Laboratories Llc Dba Blu PharmaceuticalsRIFAMPIN 300 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rifampin — NDC 42806-0799-30," retrieved September 3, 2026, https://drugdashboards.com/drug/42806079930.

Free to cite with attribution — see how the data is put together.